Gastric Cancer Overview - Raising the Standard Japanese Inspiration and a New Era of Giants

Introduction

Gastric cancer is a niche market with an incidence of 23,000 in the US alone compared with 147,000 cases of NSCLC. However, due to its large incidence, gastric cancer management in Japan is the most advanced, whereas Western markets have remained underserved. As a result, there are significant opportunities for pharmaceutical companies to develop effective drugs for gastric cancer.

Scope

* Epidemiology of gastric cancer in the seven major pharmaceutical markets (US, Japan, UK, Italy, France, Germany, Spain) 

* Current treatment strategies, including pharmacological and non-pharmacological approaches from the Japanese and the Western perspectives 

* Detailed profile of drugs in development for gastric cancer 

* Discussion of the role of screening and new surgical procedures on current and future treatments, with input from key opinion leaders

Report Highlights

The West must follow Japan’s example. Early diagnoses and better surgical expertise are key to improving survival and expanding the market for pharmacological intervention. Pharmaceutical companies could benefit from sponsoring screening pilots and surgical education programs in Western markets. 

Because of its expense relative to IV 5-FU, Roche needs to ensure that patients adequately understand Xeloda’s advantages such that physicians will more often prescribe it to suitable patients. 

By investigating the activity of both irinotecan and docetaxel in gastric cancer, a large expense for a small market, Aventis has created a win-win situation out of a seemingly confused strategy. 

Reasons to Purchase

* Examine differences between Japanese and Western prevalence, and how this has influenced the evolution of gastric cancer treatment in each market 

* Know which ongoing trials to watch and compare the clinical trial results for the most promising new gastric cancer agents 

* Gain opinion leader insight into the potential of new gastric cancer agents 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a199